title: Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer.
abstract: Fifty-four evaluable patients with SCLC previously treated with chemotherapy received either N-methylformamide or spirogermanium. There was one partial response to N-methylformamide. The median survival times for patients treated with N-MF and spirogermanium were 11.7 and 12.6 weeks respectively. Five patients treated with N-MF experienced severe toxicity while four patients treated with spirogermanium experienced severe and life-threatening toxicity.
authors.affiliation: Johns Hopkins Oncology Center, Baltimore, MD.
authors.forename: D S
authors.initials: DS
authors.lastname: Ettinger
authors.forename: D M
authors.initials: DM
authors.lastname: Finkelstein
authors.forename: M D
authors.initials: MD
authors.lastname: Abeloff
authors.forename: Y C
authors.initials: YC
authors.lastname: Chang
authors.forename: T J
authors.initials: TJ
authors.lastname: Smith
authors.forename: M M
authors.initials: MM
authors.lastname: Oken
authors.forename: J C
authors.initials: JC
authors.lastname: Ruckdeschel
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005559:Formamides / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D005559:Formamides; D009942:Organometallic Compounds; D013141:Spiro Compounds; C026818:spirogermanium; C002950:methylformamide